when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

HENGRUI PHARMA · news · pharmadog

← back to HENGRUI PHARMA

News mentioning HENGRUI PHARMA

22 stories

13dTreasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing dealsfiercebiotech

14dESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps upfiercebiotech

15dLilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platformbiospace

27dViatris boosts pain drug portfolio with $1.7B buyout of Pacirabiopharma dive

Oct 2, 26Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOSbiospace

Sep 30, 26Lilly sets up next-gen obesity battle with full phase 3 retatrutide datafiercebiotech

Sep 29, 26Novo to pay Hengrui up to $2.6B for a once-weekly obesity pillbiopharma dive

Sep 29, 26STAT+: AstraZeneca invests $2 billion in Summit Therapeuticsstat

Sep 29, 26STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and morestat

Sep 29, 26Novo adds long-term obesity differentiation in up to $2.6B Hengrui dealbiospace

Sep 29, 26Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengruifiercebiotech

Sep 22, 26GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potentialfiercebiotech

Aug 6, 26Cardiac drug developer Braveheart banks more than $382M in IPObiopharma dive

Jul 30, 26BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this yearfiercebiotech

Jul 15, 26Braveheart, Attovia join next wave of biotech IPOsbiopharma dive

Jul 7, 26Kailera says obesity pill succeeds in late-stage trial in Chinabiopharma dive

Jul 7, 26Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trialsendpoints

Jun 3, 26House bill aims to crack down on China biotech dealsbiopharma dive

May 12, 26STAT+: Hims’ sales miss as telehealth competition growsstat

May 12, 26Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billionbiopharma dive

May 12, 26Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2Bendpoints

May 12, 26STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugsstat